Isotipo central

Turning disorder druggable


INTRAMETICS™ Platform revolutionizes drug discovery, empowering design against Intrinsically Disordered Proteins (IDPs)

IDP Pharma is a clinical stage company harnessing its proprietary INTRAMETICS™ platform to tackle long-quested disease drivers: intrinsically disordered proteins (IDPs). Our molecules activate the degradation of IDPs through the intrinsic cells machinery, representing breakthrough treatments for incurable diseases/cancers.



Santiago Esteban, PhD

Co-founder & CEO

Laura Nevola, PhD

Co-founder & CSO/COO

Tim Hammond, PhD

Chief Development Officer

Laura Orozco

Head of Finance

Fabiana Subrizi, PhD

Head of R&D

David Molina, PhD

Clinical Operations Manager

Maria Fernanda Montenegro, PhD

Head of Biology

Scientific Advisory Board

Tomi Sawyer

PhD (President at Maestro Therapeutics)

Dean W. Felsher

M.D. Ph.D. (Stanford University)

Jane E. Johnson

PhD. (UT Southwestern Medical Center; Shirley and William S. McIntyre Distinguished Chair in Neuroscience)

Sir Peter John Ratcliffe (Nobel Laureate)

FRS, FMedSci (University of Oxford; Francis Crick Institute)

Andrew Spencer

MBBS, FRACP, FRCPA, DM (Alfred Health-Monash University)

Diseño sin título

Breaking New Ground: IDP-121 Clinical Trial for MYC-Driven Hematological Cancers

IDP Pharma is currently conducting a clinical trial in individuals with MYC-driven hematological cancers. This phase I/Ib clinical study (CASSANDRA) is underway at renowned hospital centers across Spain and aims to evaluate the safety, tolerability, and anti-tumor activity of IDP-121 in selected cancer patients. Details about the IDP-121 clinical trial can be found at under identifier: NCT05908409.

Link to